The serum concentration of Afatinib can be increased when it is combined with Citalopram. Fluconazole may increase the QTc-prolonging activities of Citalopram. The metabolism of Timolol can be decreased when combined with Citalopram. The metabolism of Donepezil can be decreased when combined with Citalopram. The metabolism of Flecainide can be decreased when combined with Citalopram. The metabolism of Ponatinib can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Benperidol. The risk or severity of adverse effects can be increased when Citalopram is combined with Selegiline. The risk or severity of adverse effects can be increased when Citalopram is combined with Ritanserin. Citalopram may increase the hypoglycemic activities of Exenatide. Citalopram may increase the anticoagulant activities of Fluindione. The metabolism of Pindolol can be decreased when combined with Citalopram. Furazolidone may increase the serotonergic activities of Citalopram. The metabolism of Diazepam can be decreased when combined with Citalopram. The metabolism of Enclomiphene can be decreased when combined with Citalopram. The metabolism of Citalopram can be decreased when combined with Clarithromycin. The risk or severity of adverse effects can be increased when Metoclopramide is combined with Citalopram. Hydroxyzine may increase the QTc-prolonging activities of Citalopram. Levomethadyl Acetate may increase the serotonergic activities of Citalopram. Heroin may increase the serotonergic activities of Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin. The metabolism of Nifedipine can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Zotepine. Isradipine may increase the QTc-prolonging activities of Citalopram. The risk or severity of adverse effects can be increased when Acepromazine is combined with Citalopram. The metabolism of Chlorzoxazone can be decreased when combined with Citalopram. Butorphanol may increase the serotonergic activities of Citalopram. The metabolism of Methamphetamine can be decreased when combined with Citalopram. The metabolism of Nilutamide can be decreased when combined with Citalopram. The serum concentration of Vincristine can be increased when it is combined with Citalopram. The metabolism of Caffeine can be decreased when combined with Citalopram. Normethadone may increase the serotonergic activities of Citalopram. Rilpivirine may increase the QTc-prolonging activities of Citalopram. The serum concentration of Citalopram can be decreased when it is combined with Rifampicin. Ofloxacin may increase the QTc-prolonging activities of Citalopram. Citalopram may increase the hypoglycemic activities of Canagliflozin. The metabolism of Fluvastatin can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Citalopram. The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram. Octreotide may increase the QTc-prolonging activities of Citalopram. Citalopram may increase the hypoglycemic activities of Sitagliptin. The serum concentration of Citalopram can be increased when it is combined with Nicardipine. Octamoxin may increase the serotonergic activities of Citalopram. The metabolism of Ulipristal can be decreased when combined with Citalopram. Palonosetron may increase the serotonergic activities of Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Fentanyl. The risk or severity of adverse effects can be increased when Citalopram is combined with Zolmitriptan. The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Citalopram. The serum concentration of Citalopram can be decreased when it is combined with Mitotane. The metabolism of Cisapride can be decreased when combined with Citalopram. Benmoxin may increase the serotonergic activities of Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Sumatriptan. L-Tryptophan may increase the serotonergic activities of Citalopram. The metabolism of Citalopram can be decreased when combined with Clemastine. The risk or severity of adverse effects can be increased when Pizotifen is combined with Citalopram. The metabolism of Citalopram can be decreased when combined with Sildenafil. The metabolism of Estrone sulfate can be decreased when combined with Citalopram. The metabolism of Seratrodast can be decreased when combined with Citalopram. The serum concentration of Everolimus can be increased when it is combined with Citalopram. Etoperidone may increase the serotonergic activities of Citalopram. Tropisetron may increase the serotonergic activities of Citalopram. The metabolism of Macitentan can be decreased when combined with Citalopram. The metabolism of Morphine can be decreased when combined with Citalopram. The metabolism of Tetrabenazine can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Amoxapine is combined with Citalopram. Citalopram may increase the anticoagulant activities of Ethyl biscoumacetate. The metabolism of Ifosfamide can be decreased when combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Zucapsaicin. The risk or severity of adverse effects can be increased when Bupropion is combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Cholecalciferol. The metabolism of Enfuvirtide can be decreased when combined with Citalopram. Citalopram may decrease effectiveness of Ioflupane I-123 as a diagnostic agent. The risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram. The metabolism of Gliclazide can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Norflurane is combined with Citalopram. The metabolism of Citalopram can be decreased when combined with Cinacalcet. Citalopram may increase the antiplatelet activities of Valdecoxib. The risk or severity of adverse effects can be increased when Citalopram is combined with Phenelzine. The metabolism of Guanfacine can be decreased when combined with Citalopram. The metabolism of Quinine can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Cetirizine is combined with Citalopram. The metabolism of Levobupivacaine can be decreased when combined with Citalopram. Dezocine may increase the serotonergic activities of Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Paliperidone. The risk or severity of adverse effects can be increased when Citalopram is combined with Ergonovine. Lapatinib may increase the QTc-prolonging activities of Citalopram. The risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Amisulpride. Methotrimeprazine may increase the QTc-prolonging activities of Citalopram. The serum concentration of Agomelatine can be increased when it is combined with Citalopram. The metabolism of Lansoprazole can be decreased when combined with Citalopram. Citalopram may increase the hypoglycemic activities of Rosiglitazone. The serum concentration of Citalopram can be increased when it is combined with Delavirdine. Telavancin may increase the QTc-prolonging activities of Citalopram. The metabolism of Carvedilol can be decreased when combined with Citalopram. The metabolism of Benzphetamine can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Triazolam is combined with Citalopram. Pirlindole may increase the serotonergic activities of Citalopram. The risk or severity of adverse effects can be increased when Proparacaine is combined with Citalopram. The metabolism of Trabectedin can be decreased when combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Modafinil. The metabolism of Citalopram can be decreased when combined with Lovastatin. The metabolism of Dextroamphetamine can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Propericiazine. The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Ergotamine. The serum concentration of Citalopram can be increased when it is combined with Isoniazid. The metabolism of Ibrutinib can be decreased when combined with Citalopram. The metabolism of Tofacitinib can be decreased when combined with Citalopram. The metabolism of Benzyl alcohol can be decreased when combined with Citalopram. The metabolism of Resveratrol can be decreased when combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Tranylcypromine. The serum concentration of Cilostazol can be increased when it is combined with Citalopram. The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Citalopram. Citalopram may increase the hypoglycemic activities of Insulin Aspart. The metabolism of Simvastatin can be decreased when combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Ceritinib. Trazodone may increase the QTc-prolonging activities of Citalopram. The metabolism of Adinazolam can be decreased when combined with Citalopram. The metabolism of Dapsone can be decreased when combined with Citalopram. The metabolism of Carisoprodol can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Halazepam is combined with Citalopram. The metabolism of Lomustine can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram. The metabolism of Dronabinol can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Citalopram. The risk or severity of adverse effects can be increased when Gepirone is combined with Citalopram. The metabolism of Zolpidem can be decreased when combined with Citalopram. Sulfamethoxazole may increase the QTc-prolonging activities of Citalopram.